The MEK Inhibitor Trametinib Improves Outcomes following Subarachnoid Haemorrhage in Female Rats
Aneurysmal subarachnoid haemorrhage (SAH) is a haemorrhagic stroke that causes approximately 5% of all stroke incidents. We have been working on a treatment strategy that targets changes in cerebrovascular contractile receptors, by blocking the MEK/ERK1/2 signalling pathway. Recently, a positive eff...
Saved in:
Main Authors: | Jesper Peter Bömers (Author), Anne-Sofie Grell (Author), Lars Edvinsson (Author), Sara Ellinor Johansson (Author), Kristian Agmund Haanes (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Isotretinoin for the treatment of severe acneiform eruptions associated with the MEK inhibitor trametinib
by: Marco Caruana, MD, et al.
Published: (2020) -
Trametinib, a MEK1/2 Inhibitor, Protects Mice from Cisplatin- and Noise-Induced Hearing Loss
by: Richard D. Lutze, et al.
Published: (2024) -
Microglial heterogeneity after subarachnoid haemorrhage
by: Ian Galea
Published: (2022) -
Clinical Practice Guidelines for Subarachnoid Haemorrhage Treatment
by: José Ramón Tejera del Valle, et al.
Published: (2009) -
Clinical Practice Guidelines for Subarachnoid Haemorrhage Treatment
by: José Ramón Tejera del Valle, et al.
Published: (2009)